Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a syntheti… Read more
Market Cap & Net Worth: Pharma Mar S.A. (PHM)
Pharma Mar S.A. (MC:PHM) has a market capitalization of $1.49 Billion (€1.45 Billion) as of March 19, 2026. Listed on the MC stock exchange, this Spain-based company holds position #6710 globally and #12 in its home market, demonstrating a 1.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharma Mar S.A.'s stock price €84.50 by its total outstanding shares 17174626 (17.17 Million).
Pharma Mar S.A. Market Cap History: 2015 to 2026
Pharma Mar S.A.'s market capitalization history from 2015 to 2026. Data shows growth from $505.82 Million to $1.49 Billion (5.35% CAGR).
Pharma Mar S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharma Mar S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.96x
Pharma Mar S.A.'s market cap is 5.96 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
17.61x
Pharma Mar S.A.'s market cap is 17.61 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $546.12 Million | $180.94 Million | -$24.08 Million | 3.02x | N/A |
| 2017 | $499.77 Million | $179.34 Million | -$26.75 Million | 2.79x | N/A |
| 2018 | $219.66 Million | $162.16 Million | -$5.54 Million | 1.35x | N/A |
| 2019 | $719.43 Million | $85.82 Million | -$9.18 Million | 8.38x | N/A |
| 2020 | $1.20 Billion | $269.96 Million | $137.26 Million | 4.43x | 8.72x |
| 2021 | $966.48 Million | $229.83 Million | $92.86 Million | 4.21x | 10.41x |
| 2022 | $1.10 Billion | $196.34 Million | $49.36 Million | 5.59x | 22.25x |
| 2023 | $711.78 Million | $158.15 Million | $1.14 Million | 4.50x | 626.01x |
| 2024 | $1.41 Billion | $174.85 Million | $26.12 Million | 8.05x | 53.85x |
| 2025 | $1.32 Billion | $221.39 Million | $74.99 Million | 5.96x | 17.61x |
Competitor Companies of PHM by Market Capitalization
Companies near Pharma Mar S.A. in the global market cap rankings as of March 19, 2026.
Key companies related to Pharma Mar S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pharma Mar S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Pharma Mar S.A.'s market cap moved from $505.82 Million to $ 1.49 Billion, with a yearly change of 5.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.49 Billion | +12.82% |
| 2025 | €1.32 Billion | -6.14% |
| 2024 | €1.41 Billion | +97.65% |
| 2023 | €711.78 Million | -35.19% |
| 2022 | €1.10 Billion | +13.64% |
| 2021 | €966.48 Million | -19.27% |
| 2020 | €1.20 Billion | +66.40% |
| 2019 | €719.43 Million | +227.52% |
| 2018 | €219.66 Million | -56.05% |
| 2017 | €499.77 Million | -8.49% |
| 2016 | €546.12 Million | +7.97% |
| 2015 | €505.82 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Pharma Mar S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.49 Billion USD |
| MoneyControl | $1.49 Billion USD |
| MarketWatch | $1.49 Billion USD |
| marketcap.company | $1.49 Billion USD |
| Reuters | $1.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.